TotalMarketCap

ImmunityBio

IBRXNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$8.484 B

$8.01 -10.36%

Close of 6 Nov 2026

As of 6 Nov 2026, ImmunityBio (IBRX) has a market capitalization of $8.48B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$113.3M

#2447 by revenue

Earnings

-$351.5M

Loss-making

Shares outstanding

1,059,836,273

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #15VaxcytePCVX$9.84B
  2. #16Krystal BiotechKRYS$8.92B
  3. #17ImmunityBioIBRX$8.48B
  4. #18Twist BioscienceTWST$7.95B
  5. #19ImmunovantIMVT$5.87B

What if ImmunityBio were worth as much as…

Open the what-if tool →

Gold $28.2T

$26,642.68

Per share 3,328× higher

Bitcoin $1.53T

$1,441.59

Per share 180× higher

Apple $5.02T

$4,732.60

Per share 591× higher

Or at a round number

$20.0B$50.0B$100.0B$200.0B

Where these numbers come from

Share counts and financials for ImmunityBio are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.